| Mon, 23 Apr 2018 15:30:16: | Fresenius dumps its $4.3B Akorn buyout, and a 'legal battle royale' could come next
|
| Mon, 23 Apr 2018 14:58:01: | FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info
|
| Mon, 23 Apr 2018 13:39:35: | Squeezed Mylan axing 500 jobs in West Virginia to 'right-size' massive plant
|
| Mon, 23 Apr 2018 13:07:58: | Pfizer's first U.K. ads for OTC Viagra put erectile dysfunction in perspective
|
| Mon, 23 Apr 2018 01:35:48: | Boehringer Ingelheim expands adherence-improving respiratory rewards program
|
| Sat, 21 Apr 2018 05:49:16: | After some Thursday drama, Shire weighs Takeda's cash-sweetened $61.5B offer
|
| Fri, 20 Apr 2018 15:11:08: | Novartis pads case for new MS blockbuster with disease-progression analysis
|
| Fri, 20 Apr 2018 13:34:46: | Sanofi's Dengvaxia needs a dengue diagnostic, stat, thanks to WHO
|
| Fri, 20 Apr 2018 12:57:04: | FiercePharmaAsia—Tussle for Shire, Hanmi’s EGFR bail, Grail’s $1B pre-IPO round
|
| Fri, 20 Apr 2018 05:56:41: | Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year
|
| Thu, 19 Apr 2018 22:42:18: | Allergan pulls out of Shire deal talks just hours after disclosing it was in the mix
|
| Thu, 19 Apr 2018 14:53:40: | Cosentyx woes, generics weakness cast cloud on otherwise solid Q1 for Novartis
|
| Thu, 19 Apr 2018 14:50:22: | Pharma ads on the brain: DTC on lifestyle sites triggers a bigger emotional punch
|
| Thu, 19 Apr 2018 14:20:30: | Allergan swoops in as Takeda's third Shire bid falls short at $61B
|
| Thu, 19 Apr 2018 13:10:09: | Greek lawmakers hand off probe of politicians accused of taking Novartis bribes: report
|
| Thu, 19 Apr 2018 13:05:50: | AstraZeneca's Tagrisso just got the lung cancer nod it needs to hit $3B in sales
|
| Thu, 19 Apr 2018 12:24:03: | Merck KGaA, not Pfizer, lands consumer health deal with P&G worth $4.2B
|
| Wed, 18 Apr 2018 19:13:43: | Amid tough respiratory competition, AstraZeneca inks Symbicort outcomes-based deals
|
| Wed, 18 Apr 2018 15:15:13: | How big is too big for a CEO bonus target? Annoyed Shire investors have some ideas
|
| Wed, 18 Apr 2018 15:14:36: | Sanofi scouts replacement for CFO Jérôme Contamine, who's retiring after an eventful 9 years
|
| Wed, 18 Apr 2018 13:39:43: | Ultragenyx nabs blockbuster FDA nod for $200K-per-year Crysvita
|
| Wed, 18 Apr 2018 13:23:15: | Armed with first-ever FDA nod, Rigel preps May launch for autoimmune drug Tavalisse
|
| Wed, 18 Apr 2018 13:06:58: | Novo Nordisk tackles outcomes and affordability with pilot tying copays to adherence
|
| Wed, 18 Apr 2018 02:33:53: | Lilly highlights 'relentless' women in first ads for breast cancer med Verzenio
|
| Tue, 17 Apr 2018 19:26:55: | Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head phase 3
|
